The Contribution of Epigenetics to Cancer Immunotherapy
Villanueva, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Álvarez-Errico, Damiana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer management. Nonetheless, not all patients benefit from such therapies because they fail to achieve complete responses, suffer frequent relapses, or develop potentially life-threatening toxicities. Epigenomic signatures in immune and cancer cells appear to be accurate and promising predictors of patient outcomes with immunotherapy. In addition, combined treatments with epigenetic drugs can exploit the dynamic nature of epigenetic changes to potentially modulate responses to immunotherapy. Candidate epigenetic biomarkers may provide a rationale for patient stratification and precision medicine, thus maximizing the chances of treatment success while minimizing unwanted effects. We present a comprehensive up-to-date view of potential epigenetic biomarkers in immunotherapy and discuss their advantages over other indicators.
Grants:	Agencia Estatal de Investigación RTI2018-094049-B-I00 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1080
Note:	Altres ajuts: This work was supported by the the Cellex Foundation; and La Caixa Banking Foundation (LCF/PR/GN18/51140001).
Note:	Altres ajuts: PERIS/SLT-002-16-00374
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article de revisió ; Article ; Versió publicada
Subject:	Checkpoint inhibitors ; HDAC inhibitor ; Hepatocellular carcinoma ; M1 macrophages ; PD-1/PD-L1 expression ; T regulatory cells
Published in:	Trends in Immunology, Vol. 41 Núm. 8 (august 2020) , p. 676-691, ISSN 1471-4981

DOI: 10.1016/j.it.2020.06.002
PMID: 32622854

16 p, 2.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Published articles